EcoDrugPlus

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSSDUG00000001360
Gene Symbol: PTPRB
4 Cross references
203 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSSDUG00000013803
Gene Symbol: PTPRB
4 Cross references
189 Possible Orthologues:

Protein-Serine O-Palmitoleoyltransferase Porcupine-Like

Ensembl ID : ENSSDUG00000000740
Gene Symbol: LOC111219005
3 Cross references
197 Possible Orthologues:

Protein-Tyrosine Kinase 2-Beta-Like

Ensembl ID : ENSSDUG00000014546
Gene Symbol: LOC111237992
3 Cross references
195 Possible Orthologues:

Protein-Tyrosine Kinase 6-Like

Ensembl ID : ENSSDUG00000007186
Gene Symbol: LOC111235000
3 Cross references
159 Possible Orthologues:

Proteinase-Activated Receptor 1-Like

Ensembl ID : ENSSDUG00000023504
Gene Symbol: LOC111239586
3 Cross references
263 Possible Orthologues:

Proto-Oncogene Tyrosine-Protein Kinase Src

Ensembl ID : ENSSDUG00000004836
Gene Symbol: LOC111235128
3 Cross references
197 Possible Orthologues:

Purinergic Receptor P2x 7

Ensembl ID : ENSSDUG00000013676
Gene Symbol: P2RX7
3 Cross references
191 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSSDUG00000014304
Gene Symbol: P2RY1
3 Cross references
190 Possible Orthologues:

Purinergic Receptor P2y2

Ensembl ID : ENSSDUG00000001786
Gene Symbol: P2RY2
3 Cross references
197 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSSDUG00000019185
Gene Symbol: P2RY4
4 Cross references
165 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSSDUG00000001681
Gene Symbol: P2RY6
4 Cross references
182 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).